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Current treatments for Candida albicans infection are limited due to the limited number of antifungal drugs available and the
increase in antifungal resistance. Curcumin is used as a spice, food preservative, flavoring, and coloring agent that has been shown
to have many pharmacological activities.(us, this study evaluated the modulatory effects of curcumin onmajor virulence factors
associated with the pathogenicity of C. albicans. (e minimum inhibitory concentration (MIC) of curcumin against C. albicans
(SC5314) was determined. Biofilm formation was quantified and the proteinase and phospholipase secretion was measured. (e
cytotoxicity was tested in oral fibroblast cells. A cocultured model was used to analyze the gene expression of proinflammatory
cytokines (IL-1β, IL-1α, and IL-6) from host cells, as well SAP-1 and PLB-1 by RT-PCR. (e MIC was between 6.25 and 12.5 µM,
and the activity of proteinase enzyme was significantly decreased in biofilms treated with curcumin. However, proteinase gene
expression was not downregulated after curcumin treatment. Furthermore, gene expressions of host inflammatory response, IL-
1β and IL-1α, were significantly downregulated after exposure to curcumin. In conclusion, curcumin exhibited antifungal activity
against C. albicans and modulated the proteolytic enzyme activities without downregulating the gene expression. In host in-
flammatory response, curcumin downregulated IL-1β and IL-1α gene expression.
1. Introduction
Candida albicans is a prevalent opportunistic fungus that
becomes pathogenic in patients with reduced immune
competence or in individuals with an imbalance of com-
peting bacterial microflora [1–3]. (e pathogenicity of the
Candida species is attributed to critical virulence factors,
such as the ability to evade host defenses, adhere to surfaces
(on tissues and medical devices), biofilm formation, and the
production of proteolytic enzymes, such as secreted aspartyl
proteases (SAP) and phospholipases [4].
Current treatments for C. albicans infection consist of
topical and systemic pharmaceutical antifungal agents [5].
Antifungal resistance has been increasing due to the limited
number of antifungal treatments available and the wide-
spread use of these drugs [6, 7]. (erefore, the discovery of
new and effective antifungal therapeutic agents is a necessity.
Natural compounds are readily available in many foods and
beverages.(ey are a source of molecules with antimicrobial,
anti-inflammatory, and antioxidant potential [8].
Polyphenols are secondary metabolites found in many
plants, which have been used for thousands years in tra-
ditional herbal remedies due to their diverse biological
activities [9]. Protective effects of such flavonoids have been
reported against cancer, cardiovascular diseases, diabetes,
infectious disease, as well as age-linked conditions, which
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renders them potential therapeutic agents [10]. Curcumin is
a yellow pigment derived from the roots of Curcuma longa
plants that is commonly used as a spice, food preservative,
flavoring, and coloring agent in Asia and India [10–12].
Curcumin has been shown to have many pharmacological
activities including antioxidant, anti-inflammatory, antivi-
ral, antitumor, and antibacterial activities [13]. Moreover,
curcumin acts as a photosensitizer for photodynamic therapy
with clinical application for pharyngotonsillitis, with the
proposal to reduce the use of antibiotics [14].
Based on the indexed literature, we hypothesized that
curcumin can affect the virulence factors of Candida albi-
cans and the host immune response to the pathogen.(e aim
of this study was to investigate the modulatory effects of
curcumin in vitro in some virulence factors associated with
the pathogenicity of Candida albicans. Proteolytic enzyme
activities secreted by C. albicans were quantified in addition
to gene expression of inflammatory cytokines marker of the
host in a coculture system. Ultimately, this study explored
the mechanisms by which curcumin can modulate the
pathogenicity of Candida albicans and validated the phar-
macological effects of curcumin.
2. Materials and Methods
2.1. Susceptibility Test. Antimicrobial activity of curcumin
(Sigma-Aldrich; St. Louis, MO) was tested in vitro according
to the NCCLS guidelines against Candida albicans strain
(ATCC SC5314/MYA2876). Curcumin concentrations ranged
from 1.5 to 400 μM. Fluconazole (322 μM) (Sigma) and 1%
dimethyl sulfoxide (DMSO) (v/v) (Sigma-Aldrich; St. Louis,
MO) served as a positive control and vehicle control, re-
spectively.(e minimum inhibitory concentration (MIC) was
determined using an inoculum of 5×103CFU/ml. C. albicans
were grown in RPMI-1640 (Lonza, Walkersville, MD) in a 96-
well plate, and incubated for 24 h at 37°C in 5% CO2. After
24 h, the MIC was determined visually, and the minimum
fungicidal concentration (MFC) was found by subculturing
20μl from each concentration above the MIC on Sabouraud
dextrose agar (Becton Dickinson, Franklin Lakes, NJ) for 48
hours at 37°C in 5% CO2 [15].
2.2. Biofilm Assay. One milliliter of 1× 106 CFU/ml C.
albicans inoculum was added in each well of a sterile 24-well
plate, suspended in yeast nitrogen base medium (Becton
Dickinson, Franklin Lakes, NJ) with 50mM of glucose. (e
plate was incubated for 24 h (37°C in 5% CO2) to allow initial
biofilm growth and adhesion to the plate surface. Biofilms
were then treated every 24 h using curcumin concentrations
of 62.5 μM and 125 μM (10x MIC and 20x MIC resp.) for
three days. Before each treatment, biofilms were washed with
500 μl of PBS and replenished with 900 μl of fresh medium
and 100 μl of curcumin treatments. (e 1% ethanol was used
as vehicle control, and fluconazole (1mg/ml) served as
a positive control. On the fifth day, biofilms were washed
with PBS and the biomass was measured.
PBS (1mL) was added to each well, and the biofilm was
suspended to disrupt the biofilm formation. Viability and
colony formation unit (CFU) of C. albicanswere determined
by plating 20 μl of the suspended biofilm solution on Sab-
ouraud dextrose agar plates (Becton Dickinson, Franklin
Lakes, NJ). (e plates were incubated for 24 h at 37°C in 5%
CO2, and the number ofC. albicans colonies was counted. To
determine the dry weight of the biofilm sample, C. albicans
suspended in PBS solution was centrifuged at 10,000 rpm for
5 minutes. (e supernatant was discarded and the sample
was placed in a speed vacuum to dry for 40 minutes, and dry
biofilm mass was determined [16].
2.3. Cell Viability Test. Oral fibroblast cells (ATCC:
CRL2014) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Lonza, Walkersville, MD) with 10% fetal
bovine serum (FBS, Lonza, Walkersville, MD) at 37°C in 5%
CO2. Fibroblast cells (1× 105 cells/ml) were first seeded in
each well of a 96-well plate in DMEMwith 10% FBS, and the
plates were incubated for 24 h at 37°C in 5% CO2.(en, cells
were treated with curcumin (1.5–640 μM), and the plates
were incubated at 37°C in 5% CO2 for 24 h. Cell viability
was measured by the fluorometric method (Cell Titer Blue,
Promega Corp,Madison,WI) in a SpectraMaxM5microplate
reader (Molecular Devices Sunnyvale, CA) with 550 nm
(Ex)/585 nm (Em) wavelength [17].
2.4. Proteinase and Phospholipase Enzyme Secretion Assay.
Proteinase and phospholipase enzyme secretion assays were
conducted as previously performed by Santana et al. [15].
Biofilms of C. albicans were grown as described before and
treated for 72 h using curcumin (62.5 μM and 125 μM) and
the standards: phospholipase A2 (Sigma-Aldrich; St. Louis,
MO) and trypsin (Lonza, Walkersville, MD) for proteinase
assay. (e vehicle control was 1% ethanol. C. albicans
biofilms were sonicated, and the proteinase enzyme activity
was determined by mixing the supernatant of the biofilm
solution with 1% azocasein at 1 : 9 (v/v) for 1 h at 37°C in 5%
CO2. (en, 500 μl of 10% trichloroacetic acid was added to
stop the reaction. (e solutions were centrifuged for 5
minutes at 10,000 rpm. (e supernatant (500 μl) was com-
bined with 500 μl of NaOH and incubated at 37°C in 5% CO2
for 15min. (e absorbance was read at 440 nm using
a spectrophotometer [5, 13, 17]. (e phospholipase enzyme
activity is determined by mixing the supernatant of the
biofilm solution with phosphatidylcholine substrate for 1 h
at 37 °C in 5% CO2. Absorbance was read in a spectropho-
tometer at 630 nm [13, 15, 18].
2.5. Coculture Model Quantitative Real-Time PCR.
Fibroblast cells (1× 105 cells/ml) were seeded in a 96-well
plate in DMEM medium with 10% FBS and incubated at
37°C in 5% CO2 for 24 h. (e medium was replaced, and C.
albicans inoculum of 5×103 to 2.5×103 CFU/ml in DMEM
without FBS was added. Fibroblast cells and C. albicans were
treated with 20 μM and 40 μM (subcytotoxic dose) of cur-
cumin. (e plates were incubated for 24 h. (e vehicle
control tested was 1% ethanol, while fluconazole was the
positive control. Total RNA was isolated from fibroblast cells
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and C. albicans. e RNA was puried using the RNeasy
MiniKit (Qiagen, Valencia CA) and the RiboPure Yeast Kit
(Life Technologies, Carlbad, CA), respectively. A Nano-
Photometer P360 (Implen; Westlake Village, CA) was used
to quantify the total RNA extracted. Reverse transcription of
the RNA into cDNA was carried out using iScript Advanced
cDNA synthesis Kit for RT-qPCR (BioRad, Hercules, CA)
according to the manufacturer’s instructions. Real-time PCR
was conducted using iQ SYBR Green Supermix (BioRad,
Hercules, CA).eC. albicans primers for the genes secreted
aspartyl proteinases-1 (SAP-1), phospholipase B-1 (PLB-1),
and ACT-1 (housekeeping) at 10 μM were used [19]. Based
on previous analysis using the RT2 Proler PCR Array Kit
(Qiagen, Valencia CA), the following broblast genes were
selected: IL1-α (Qiagen Gene ID#: 3552), IL1-β (Qiagen
Gene ID#: 3553), IL-6 (Qiagen Gene ID#: 3569), and
GADPH (Qiagen Gene ID#: 2597). PCR amplication was
performed using 20 μl of the reaction mix in each of the 96-
well plate. e reactions were conducted at 95°C for 3
minutes, followed by 40 cycles of 15 seconds at 95°C and 1
minute at 60°C. After PCR, the melting curve was obtained
by incubating the samples at increasing increments of 0.5°C
from 55°C to 95°C.
2.6. Statistical Analysis. Data were tested for normal dis-
tribution by Shapiro–Wilks’ test, and the equivalence of
variances were tested by Levene’s test. All data were expressed
as the mean± SEM using one-way analysis of variance
(ANOVA) and Dunnett’s multiple comparison tests in re-
lation to the vehicle.e level of statistical signicance was set
at 0.05. e lethal dosage (LD50) was found using nonlinear
regression analysis by MasterPlex 2010 Reader Fit. PCR
analysis was performed using the ΔΔCt method.
3. Results
e MIC for curcumin against C. albicans was in a range
between 6.25 μM and 12.5 μM. e biolm assay results
showed a decrease in the mass of biolms treated with
curcumin (62.5 μM and 12.5 μM) in relation to the vehicle
control (Figure 1). However, the results were not statistically
signicant (p> 0.05). Concentrations of curcumin below
40 μM showed no signicant cytotoxicity against oral -
broblast cells when compared to the vehicle (data not
shown), and the LD50 was 48.75 μM.
After treatments with curcumin at 62.5 μM and 125 μM,
there was a signicant decrease (p< 0.05) in the proteinase
and phospholipase enzyme activity when compared to the
vehicle (Figures 2(a) and 2(b)). ere were no di§erences in
the expression of SAP-1 after exposure to curcumin (Fig-
ure 3(a)). e treatment with 10 μM curcumin signicantly
increased the PLB-1 gene expression in comparison to the
vehicle. However, there was no di§erence between curcumin
at 20 μM and vehicle (Figure 3(b)). e expression of host
in¨ammatory markers showed a signicant downregulation
in IL-α and IL1-β with curcumin treatment at 10 μM and
20 μM.ere were no changes in the expression of IL-6 gene
for both curcumin treatments (Figure 4).
4. Discussion
e resistance of Candida species to conventional antifungal
agents, such as triazoles, represents a major challenge for the
treatment of candidiasis especially in individuals with di-
minished immune response, for example, in HIV patients.
Natural compounds are potential therapeutic agents that
may be considered for the treatment of fungal infection
because of their antimicrobial benets. Over the past 30
years, the FDA has recognized 69% of 109 small molecules
from natural products or derivates as having antimicrobial
e§ects [20].
Curcumin stands as a potential antimicrobial natural
compound, which is incorporated as an important traditional
remedy spice used by the traditional Asian and Indian culture.
However, scientic validation of its antimicrobial e«cacy,
toxicity e§ects, and mechanism of action are necessary to
establish its safety for therapeutic purposes. us, this study
demonstrated the curcumin e§ects on virulence factors of C.
albicans, including the analysis of gene expression.
Curcumin has been reported to have antifungal activity
against various strains of Candida, including Candida
albicans (ATCC 10261), with a minimum inhibitory con-
centration (MIC) ranging from 250 to 2000 µg/ml (0.68mM
to 5.4mM) [11, 21]. In this study, we usedC. albicans SC5314
strain, and the MIC was found in the range of 6.25–12.5 µM.
C. albicans 5314 was used because the genome is fully de-
scribed, with well-known molecular patterns and pheno-
types. In addition, the biolm formation by this strain is well
established in several studies [22, 23].
In the biolm assay, ten times of MIC concentration
(62.5 µM and 125 µM) were tested because biolms have
a denser network of yeasts and hyphal population that are
more resistant to drug di§usion than to planktonic coun-
terparts. It was found that both concentrations of curcumin
did not signicantly reduce the colony formation in the
biolms normalized by the dry weight of the samples.
Possible explanation for the lack of the signicant CFU
reduction/dry weight is that curcumin did not drastically
Curcumin biofilm















Figure 1: Mean and SD of Candida albicans biolm expressed in
CFU/grams of dry weight after treatment with curcumin.
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a§ect the composition of biolms. However, this hypothesis
needs to be further investigated by studying the poly-
saccharides and protein composition of the biolm samples
upon treatment with the compound. Similarly, the biolm’s
dry weight (data not shown) did not show signicant dif-
ferences among the groups, signifying that the total biomass
compositions of all fungal cells, including dead/live cells,
were not a§ected with treatment of any compound.
e lethal dosage or 50% cell viability (LD50) was
48.75 μM, which is important to ensure the therapeutic
safety level when considering in vivo studies as well as human
clinical trials. It should also be noted that in coculture models,
curcumin has more sensitive and profound e§ect on the
morphology and distribution of broblast cells, as this model
represents “naked-cells,” that have a more susceptible cell
response than cells tested under clinically relevant conditions.
Proteinases and phospholipases are enzymes secreted by
Candida albicans often associated with tissue degradation,
hyphal formation, and host invasion, which are critical
factors linked to the pathogenicity of C. albicans [24, 25].
Proteinase and phospholipase enzyme activities were re-
duced using curcumin at 62.5 μM and 125 μM.ese results
suggest that one possible curcumin mechanism of action
involves inhibition of proteinase secretion, which is an
important virulence factor [21]. is nding is consistent
with the results reported by Neelofar et al. [11], in which
curcumin decreased proteinase secretion by 53% in C.
albicans compared to the vehicle control group.
SAP proteins are often associated with virulence factors
able to elicit a destructive e§ect on the host tissue during
mucosal infections, as they facilitate hyphal invasion and
activate the degradation of E-cadherin, a major protein
present in epithelial cell junction [24, 25]. In this current
study, the e§ect of curcumin on SAP-1 gene expression was
analyzed.
ere was no signicant downregulation in SAP-1 gene
expression after treatment curcumin at 10 µM and 20 µM
(Figure 3(a)). One possible explanation is based on a nega-
tive feedback mechanism modulating gene expression. Gene
expression of proteases may play an important role in
regulating the enzyme activity of proteases. us, as in-
dicated by the signicant decrease in proteolytic enzyme
activities of phospholipases and proteinases, there may be
a negative feedback inhibition regulating their respective
gene expression. However, this hypothesis needs to be
conrmed through further molecular studies.
e ability of C. albicans to attach to the host tissue is
considered a key pathogenic characteristic and an important








































Figure 2:Mean and SD ofCandida albicans proteinase (a) and phospholipase (b) enzyme secretion expressed in U/grams of dry weight after
treatment with curcumin (62.5 μM and 125 μM). ∗Statistical di§erence in relation to vehicle control, p< 0.05, ANOVA, Dunnett’s.



























Figure 3: Real-time quantitative information about gene expression of SAP-1 (a) and PLB-1 (b) after curcumin treatments (10 μM and
20 μM) in oral broblast cells infected by C. albicans. ∗Statistical di§erence between curcumin treatments and control in comparison with
vehicle, p< 0.05 ANOVA, Dunnett’s.
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virulence factor. Phospholipase B (PLB) proteins were
shown to have hydrolytic activity, as they hydrolyze acyl
ester bonds in phospholipids and lysophospholipids and
catalyze lysophospholipase-transacylase reactions. PLB
multigene family encodes for CaPLB5, a putative secretory
protein with a predicted GPI-anchor attachment site [26].
e PLB-1 gene expression after curcumin treatment was
also evaluated. Although curcumin in lowest concentration
increases the expression of PLB-1, this was not re¨ected in
the enzymatic activity.
Host immune defense plays a critical antagonistic role
during fungal infections, where the pathogenic state of
candidiasis is marked by an increase in the proin¨ammatory
cytokines [27, 28]. Gingival broblasts are major actors in
the host immune defense against C. albicans infection. Fi-
broblasts express dectin-1 on the cell surface that recognizes
C. albicans and active the in¨ammatory response by se-
creting in¨ammatory cytokines, such as IL-1β, IL-1α, IL-6,
and IL-8 [29, 30]. Proin¨ammatory cytokines play an im-
portant role in the pathogenesis of many in¨ammatory
diseases [31]. In this study, the gene expressions of the
proin¨ammatory cytokines, IL1-α, IL1-β, and IL-6, were
analyzed using host oral broblast cells infected with C.
albicans in a coculture model.
We demonstrated that curcumin can reduce the
IL-1α and IL-1β gene expression of broblasts exposed
to C. albicans infection. Similar results were observed in
C. albicans treated with monolaurin [32]. e anti-
in¨ammatory property of curcumin is well established
and has been demonstrated in di§erent cells [33, 34].
In agreement with our results, curcumin has been
reported to block the release of IL-1 in bone marrow
stromal cells, colonic epithelial cells, and human articular
chondrocytes [35].
ese cytokines promote the in¨ammation by the ac-
tivation of innate immune response and the induction of
cyclooxygenase type 2. Furthermore, these cytokines also
increase the expression of adhesion molecules, synthesis of
nitric oxide, and the release of other cytokines [36]. How-
ever, IL-6 gene expression was not a§ected after curcumin
treatments. In some systemic diseases, the IL-1 blockade
reduces the levels of IL-6 [36]. us, IL-6 gene expression
appears to be more associated with IL-1α and IL-1β levels
than with the e§ects of curcumin.





































Figure 4: Real-time quantitative information about gene expression of IL-1α (a), IL-1β (b), and IL-6 (c). ∗Statistical di§erence between
curcumin treatments and control in comparison with vehicle, p< 0.05, ANOVA, Dunnett’s.
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Curcumin suppressed the production of inflamma-
tory cytokines via regulation of molecular targets and
transcription factors [37]. In vascular smooth muscle cells,
curcumin inhibits LPS-induced inflammation by sup-
pressing the activation of TLR4, inhibiting phosphorylation
of ERK1/2 and p38 MAPK, preventing nuclear translocation
of NF-κB, and reducing NADPH-mediated intracellular
ROS production [38].
Although gingival fibroblasts are nonprofessional im-
mune cells, they also express other pattern recognition re-
ceptors, such as TLRs, that recognizes C. albicans molecular
patterns [39]. Activation of TLRs leads to activation of
transcription factors such as NF-κB and interferon regulatory
factors that induces the expression of various proin-
flammatory cytokines [40]. (e downregulation of IL-1α and
IL-1β induced by curcumin during the exposure toC. albicans
could be related to the inhibition of TLR-MAPK/NF-κB
pathways. Others anti-inflammatory mechanisms of curcu-
min in the C. albicans infection should be elucidated.
5. Conclusion
Curcumin had a slight antifungal activity against Candida
albicans (SC5314). Curcumin reduces the proteolytic en-
zyme activities of phospholipases and SAPs without
downregulating the gene expression. Furthermore, curcu-
min can modulate the host inflammatory response by de-
creasing gene expression of IL-1β and IL-1α. Future
direction for research may involve studying the synergistic
effects of curcumin and other conventional therapies on
biofilm models. In addition, the curcumin efficacy in C.
albicans strains isolated from clinical samples with different
virulence profiles should be tested.
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